Dr. Manji on Treatment for BRAF-Mutant CRC

Gulam A. Manji, MD, PhD, director, Medical Oncology and Translational Research for The Pancreas Center, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, discusses clinical trials for patients with colorectal cancer (CRC) harboring BRAF or other molecular abnormalities.

Although prognosis is poor for patients with BRAF-mutant CRC, recent combination trials that target EGFR, MAK, and BRAF mutations are showing intriguing clinical activity, according to Manji.

Manji recommends that all patients with CRC who have BRAF mutations and other abnormalities should enroll onto biomarker-driven clinical trials to help researchers get solid data that show proven benefit.